COVID-19 and celiac disease: a review

Cohen, Brandon S.; Lebwohl, Benjamin

doi:10.1177/17562848231170944

Cited by 3 publications

(3 citation statements)

References 50 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers have worked to determine whether CD patients are more likely to experience severe COVID-19 outcomes during the pandemic. Undoubtedly, the pandemic has altered how CD is managed; for example, lockdowns have necessitated the use of new technologies to provide medical care during this time [ 88 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Utilizing Telemedicine Applications in Celiac Disease and Other Gluten-Free-Diet-Dependent Conditions: Insights from the COVID-19 Pandemic

Haimi,

Lerner

2024

Healthcare

View full text Add to dashboard Cite

Background: Globally, approximately 1.4% of people have celiac disease (CD), induced by gluten sensitivity. If left untreated, it causes small intestinal inflammation and villous atrophy, which can result in failure to thrive, anemia, osteoporosis, malabsorption, and even malignancy. The only treatment option available is a gluten-free diet (GFD). Few studies have looked at the role and perception of telehealth in relation to CD and selective nutrition both before and after the COVID-19 pandemic. Aim: Our goal was to screen and investigate the research conducted both before and after the COVID-19 pandemic concerning the utilization of telehealth applications and solutions in CD and other GFD-dependent circumstances. Methods: We employed a narrative review approach to explore articles that were published in scholarly journals or organizations between the years 2000 and 2024. Only English-language publications were included. PubMed and Google Scholar searches were mainly conducted using the following keywords: telemedicine, telehealth, telecare, eHealth, m-health, COVID-19, SARS-CoV-2, celiac disease, and gluten-free diet (GFD). Manual searches of the references in the acquired literature were also carried out, along with the authors’ own personal contributions of their knowledge and proficiency in this field. Results: Only a few studies conducted prior to the COVID-19 outbreak examined the viewpoints and experiences of adult patients with CD with relation to in-person clinic visits, as well as other options such as telehealth. The majority of patients believed that phone consultations were appropriate and beneficial. Video conferencing and telemedicine became more popular during the COVID-19 pandemic, demonstrating the effectiveness of using these technologies for CD on a global basis. In recent years, urine assays for gluten identification have become accessible for use at home. These tests could be helpful for CD monitoring with telemedicine assistance. Conclusions: The extended knowledge gathered from the COVID-19 pandemic is expected to complement pre-COVID-19 data supporting the usefulness of telemedicine even after the emergent pandemic, encouraging its wider adoption in standard clinical practice. The monitoring and follow-up of CD patients and other GFD-dependent conditions can greatly benefit from telemedicine.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Nevertheless, the experience gained from the COVID-19 pandemic is likely to support pre-COVID-19 evidence regarding the efficacy and good performance of telemedicine and encourage its wider integration into routine clinical practice in general, and in CD patients in particular [ 52 , 54 , 87 , 88 ].…”

Section: Discussionmentioning

confidence: 99%

Utilizing Telemedicine Applications in Celiac Disease and Other Gluten-Free-Diet-Dependent Conditions: Insights from the COVID-19 Pandemic

Haimi,

Lerner

2024

Healthcare

View full text Add to dashboard Cite

show abstract

“…Few studies have addressed the effect of the SARS-CoV-2 vaccine in patients with celiac disease [ 14 ]. Studies from Norway and Italy showed that patients with CD had very good antibody response to vaccination that was comparable to healthy controls [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign

Ben-Tov,

Lebwohl,

Banon

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

Background: Data on COVID-19 vaccine effectiveness among patients with coeliac disease are currently lacking because patients with immune conditions were excluded from clinical trials. We used our coeliac disease autoimmunity (CDA) cohort to explore the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in preventing SARS-CoV-2 infection among patients with CDA. Methods: This retrospective cohort study included patients with positive autoantibodies against tissue transglutaminase (tTG-IgA). In the primary analysis, the cohort included CDA patients who received two vaccine doses against COVID-19 and matched patients in a 1:3 ratio. Patients were divided into subgroups based on their positive tTG-IgA level at diagnosis and their current serology status. Results: The cohort included 5381 vaccinated patients with CDA and 14,939 matched vaccinated patients. The risk for breakthrough SARS-CoV-2 infection evaluated with Kaplan–Meier survival analysis via log-rank tests was similar between groups (p = 0.71). In a Cox regression survival analysis, the hazard ratio for breakthrough infection among patients with CDA compared to matched patients was 0.91 (95% confidence interval = 0.77–1.09). Conclusions: COVID-19 vaccination is effective in patients with coeliac disease autoimmunity. Vaccine effectiveness was comparable to the reference population.

show abstract